Regulatory compliance
The TGA monitors and enforces regulatory compliance in relation to therapeutic goods. This supports consumer protection and a fair market for industry.
Latest alerts
-
Further examples of counterfeit Ozempic-labelled products have been detected and stopped at the Australian border.
-
Takeda Pharmaceuticals Australia has issued a product alert for Vyvanse capsules due to minor packaging errors. The medication is safe to use as prescribed.
-
Magnum XXL capsules pose a serious risk to your health and should not be taken.
Latest articles
-
Court proceedings initiated against Philips Electronics Australia Limited
The Therapeutic Goods Administration has commenced proceedings in the Federal Court of Australia against Philips Electronics Australia Limited (PEAL) for the alleged unlawful supply of medical devices that did not meet Australian safety and performance requirements. -
Updated GMP clearance information
Our Good Manufacturing Practice (GMP) Clearance information resources have been updated with new information for Sponsors -
Summit Pharmacy Pty Ltd issued infringement notices for the alleged unlawful manufacturing of medicinal cannabis products
We have issued 4 infringement notices totalling $75,120 to Queensland based pharmacy Summit Pharmacy Pty Ltd, for the alleged unlawful manufacturing of medicinal cannabis products.
Latest publications
-
The report cards show the progress made by the TGA in the 3 strategies that make up the Action Plan for Medical Devices.
-
Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
This plan outlines our compliance and education priorities for 2024-2025.